Press Releases
-
Advanced BioDesign Reports Immune-Activating Potential of ABD-3001, Expanding the Therapeutic Promise of its First-in-Class ALDH1 Inhibitor
Frontiers in Immunology publication reveals that ABD-3001 preserves immune function while promoting immunogenic remodeling of acute myeloid leukemia cells. Lyon, France – 18th August 2026 — Advanced BioDesign…
-
Advanced BioDesign Presents ODYSSEY Clinical Data and New Preclinical Findings Supporting Combination Strategies at EHA 2026
Lyon, France – 2nd of June 2026 — Advanced BioDesign, a biotechnology company developing first‑in‑class ALDH1 inhibitors for treatment‑resistant cancers, today announced the presentation of…
-
Advanced BioDesign Strengthens Early Access Program Outcomes, Confirms Steady Progress of ODYSSEY Clinical Trial, and Announces Upcoming Scientific Presentations
Lyon, France – 23rd of March 2026 — Advanced BioDesign, a biotechnology company developing first‑in‑class ALDH1 inhibitors for treatment‑resistant cancers, today released an update on…
-
Advanced BioDesign to Present Groundbreaking Research data on AML at the 67th ASH Annual Meeting
Lyon, France – December 5th, 2025 — Advanced BioDesign, a French clinical-stage biotechnology company focused on developing innovative therapies for treatment-resistant cancers, is proud to…
Advanced BioDesign 